Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TriSalus Life Sciences, Inc. - Common Stock (NQ:TLSI)

2.875 -0.345 (-10.71%)
Delayed Quote Updated: 3:51 PM EST, Nov 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about TriSalus Life Sciences, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
TriSalus Life Sciences Reports Third Quarter 2026 Results
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Reports Second Quarter 2026 Results
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
From Pomerantz LLP
Via GlobeNewswire
News headline image
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
From Pomerantz LLP
Via GlobeNewswire
News headline image
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
From TriSalus Life Sciences
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
From Pomerantz LLP
Via GlobeNewswire
News headline image
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
From Pomerantz LLP
Via GlobeNewswire
News headline image
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
TriSalus Life Sciences Inc. (TLSI) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
TLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities Fraud
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth
From TriSalus Life Sciences
Via Business Wire
News headline image
Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering
From TriSalus Life Sciences
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.